Neurorehabilitation News

BOSTON — Relapse rates for patients with MS who took dimethyl fumarate were consistently low over the course of 5 years, Krupa Shah Pandey, MD, said in this Healio video.

Topline results from a phase 1b/2a study evaluating an investigational therapy for C9orf72-associated ALS and frontotemporal dementia revealed no clinical benefit after 24 weeks of treatment compared with placebo.

CHICAGO — Preference for using a movement-prompting rehabilitation device was higher among adults with mild Parkinson’s disease, with safety concerns growing in those with more advanced disease, according to research.

CHICAGO — Adults with tardive dyskinesia prescribed deutetrabenazine had better adherence and were less likely to discontinue treatment compared with those on valbenazine, although the differences were not statistically significant.

CHICAGO — Use of an in-home therapy desk improved motor skills and balance and reduced sedentarism in adults with Parkinson’s disease, according to data at the International Association of Parkinsonism and Related Disorders World Congress.

CHICAGO — Deep brain stimulation was a cost-effective and clinically efficacious option for advanced Parkinson’s disease compared with medical therapy for patients in the Vietnamese health care system, according to research.

Genentech announced positive results from its global phase 2 study evaluating the investigational oral Bruton’s tyrosine kinase inhibitor fenebrutinib in adults with relapsing forms of MS.

CHICAGO — Active electrode placement in the right subthalamic nucleus in deep brain stimulation was associated with weight gain in patients with Parkinson’s disease, with lesser gain reported with medially placed electrodes.

CHICAGO — Tributyrin supplementation may have a beneficial effect on motor symptoms and inflammatory markers in Parkinson’s disease, according to data at the International Association of Parkinsonism and Related Disorders World Congress.

CHICAGO — Continuous subcutaneous apomorphine infusion reduced “off” time and increased “on” time without troublesome dyskinesia in patients with Parkinson’s disease in the United States, with no new safety signals reported.